Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 11:54 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,187 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HER2-normal Clear all

Conditions: Breast Cancer
Interventions: Palbociclib, Standard Adjuvant Endocrine Therapy; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 5,796 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 192
States / cities: Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 138 more

Conditions: Breast Cancer
Interventions: Trastuzumab Deruxtecan; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 506 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 2
States / cities: Boston, Massachusetts • Durham, North Carolina

Conditions: Breast Cancer
Interventions: trastuzumab, paclitaxel; Biological · Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2004
U.S. locations: 3
States / cities: Fort Lauderdale, Florida • Bethesda, Maryland • Morgantown, West Virginia

Conditions: Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer
Interventions: Patritumab deruxtecan, Trastuzumab deruxtecan; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 12
States / cities: Los Angeles, California • Stanford, California • Aurora, Colorado + 8 more

Conditions: Breast Cancer
Interventions: Ixabepilone, Trastuzumab, Carboplatin; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2014
U.S. locations: 12
States / cities: Fort Myers, Florida • Augusta, Georgia • Terre Haute, Indiana + 8 more

Conditions: Triple Negative Breast Cancer, Breast Neoplasms
Interventions: P10s-PADRE with MONTANIDE™ ISA 51 VG, Doxorubicin, Cyclophosphamide, Paclitaxel; Biological · Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older · Female only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Fayetteville, Arkansas • Little Rock, Arkansas

Conditions: Breast Cancer
Interventions: Abemaciclib, Anastrozole, Letrozole, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 20
States / cities: Chandler, Arizona • Springdale, Arkansas • Bakersfield, California + 13 more

Conditions: HER2-positive Metastatic Breast Cancer, Stage IV Breast Cancer
Interventions: Discontinuation of Anti-HER-2 Maintenance Treatment; Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Breast Cancer
Interventions: capecitabine [Xeloda], Taxotere, Herceptin (HER2-neu positive patients only); Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 38
States / cities: Los Angeles, California • Montebello, California • Palm Springs, California + 30 more

Conditions: HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Triple Negative Breast Cancer, Male Breast Cancer
Interventions: PF-06873600, Endocrine Therapy 1, Endocrine Therapy 2; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 39
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Fayetteville, Arkansas + 22 more

Conditions: Breast Neoplasms, Breast Cancer, Estrogen-receptor Positive Breast Cancer, Cancer, Breast, Breast Cancer Female, Breast Adenocarcinoma, Estrogen Receptor Positive Tumor, ER Positive
Interventions: H3B-6545; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 23
States / cities: Goodyear, Arizona • Los Angeles, California • San Francisco, California + 18 more

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8
Interventions: Bintrafusp Alfa, Radiation Therapy; Drug · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastases, Brain
Interventions: capecitabine, lapatinib, trastuzumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 17
States / cities: Goodyear, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 14 more

Conditions: Carcinoma, Ductal, Breast, Breast Cancer Female, Breast Neoplasm, Breast Cancer, Metastatic Breast Cancer, Advanced Breast Cancer, Stage IV Breast Cancer
Interventions: G1T48, Palbociclib; Drug
Lead sponsor: G1 Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 6
States / cities: Beverly Hills, California • Stanford, California • Chicago, Illinois + 3 more

Conditions: Breast Neoplasms
Interventions: Sacituzumab tirumotecan, Pembrolizumab, Paclitaxel, Nab-paclitaxel, Capecitabine, Liposomal doxorubicin; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 46
States / cities: Chandler, Arizona • Gilbert, Arizona • Fullerton, California + 38 more

Conditions: Estrogen Receptor-negative Breast Cancer, HER2-negative Breast Cancer, Male Breast Cancer, Progesterone Receptor-negative Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-negative Breast Cancer
Interventions: eribulin mesylate, carboplatin, biopsy; Drug · Procedure
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Breast Adenocarcinoma, HER2 Positive Breast Carcinoma, Stage IA Breast Cancer AJCC v7, Stage IB Breast Cancer AJCC v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7
Interventions: Aromatase Inhibition Therapy, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Tamoxifen Citrate, Trastuzumab; Drug · Other · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 3,436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 154
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 119 more

Conditions: Metastatic Breast Cancer, Locally Recurrent Breast Cancer
Interventions: Eribulin, Balixafortide; Drug
Lead sponsor: Spexis AG; Industry
Eligibility: 18 Years and older
Enrollment: 432 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 28
States / cities: Fresno, California • Los Angeles, California • San Francisco, California + 23 more

Conditions: Metastatic Breast Cancer
Interventions: Abemaciclib, Tamoxifen, Prophylactic Loperamide; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 5
States / cities: Tucson, Arizona • Lebanon, New Hampshire • Nashville, Tennessee + 2 more

Conditions: Breast Cancer
Interventions: Fulvestrant, BKM120, BKM120 matching placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 1,147 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 61
States / cities: Mobile, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 51 more

Conditions: Metastatic Breast Cancer, Locally Advanced Breast Cancer, Breast Cancer
Interventions: Samuraciclib, Fulvestrant; Drug
Lead sponsor: Carrick Therapeutics Limited; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 5
States / cities: Ocala, Florida • Baltimore, Maryland • Kansas City, Missouri + 2 more

Conditions: HER2-positive Breast Cancer, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions: laboratory biomarker analysis, pharmacological study, questionnaire administration, fluorine F 18-clevudine, positron emission tomography/computed tomography; Other · Radiation · Procedure
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Breast Cancer
Interventions: Doxorubicin, Cyclophosphamide, Docetaxel, Paclitaxel; Drug
Lead sponsor: NSABP Foundation Inc; Network
Eligibility: 18 Years and older · Female only
Enrollment: 4,242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2025
U.S. locations: 914
States / cities: Anchorage, Alaska • Phoenix, Arizona • Scottsdale, Arizona + 612 more

Conditions: Breast Cancer
Interventions: Amcenestrant-matching placebo, SAR439859, Palbociclib, Letrozole, Goserelin, Letrozole-matching placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 1,068 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 45
States / cities: Daphne, Alabama • Glendale, Arizona • Tucson, Arizona + 40 more

Search by objective public record fields.

PALbociclib CoLlaborative Adjuvant Study

A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer

Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer

Vaccination of Triple Negative Breast Cancer Patients

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer

Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer

XeNA Study - A Study of Xeloda (Capecitabine) in Patients With Invasive Breast Cancer

A Study of PF-06873600 in People With Cancer

Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer

Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer

G1T48, an Oral SERD, Alone and in Combination With Palbociclib in ER-Positive, HER2-Negative Advanced Breast Cancer

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)

Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients

Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer

Pivotal Study in HER2 Negative, Locally Recurrent or Metastatic Breast Cancer

A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer

Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor

A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants

PET/CT in Evaluating Response to Chemotherapy in Patients With Breast Cancer

Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer

Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer